|
NFATC3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.37518901716294E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.89700000041704E-07 |
| Normal-vs-Stage3 |
2.10997885830011E-12 |
| Normal-vs-Stage4 |
2.44249065417534E-15 |
| Stage1-vs-Stage2 |
2.770600E-01 |
| Stage1-vs-Stage3 |
2.006400E-01 |
| Stage1-vs-Stage4 |
9.579100E-04 |
| Stage2-vs-Stage3 |
4.979800E-02 |
| Stage2-vs-Stage4 |
1.940690E-03 |
| Stage3-vs-Stage4 |
6.912400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
3.49659967646687E-10 |
| Normal-vs-Asian |
1.42640343980815E-11 |
| Caucasian-vs-AfricanAmerican |
7.576200E-01 |
| Caucasian-vs-Asian |
5.901200E-01 |
| AfricanAmerican-vs-Asian |
8.446400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.43849426498855E-14 |
| Normal-vs-Female |
2.63589150506505E-12 |
| Male-vs-Female |
4.400600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.626032641866E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
5.4802828941547E-12 |
| Normal-vs-Age(81-100Yrs) |
1.117110E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.069600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.380800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.833000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.600000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.499800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.333400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.171810E-02 |
| Classical-VS-Follicular |
8.974400E-01 |
| Classical-VS-Other |
3.325000E-01 |
| Classical-VS-Normal |
2.28299601445769E-11 |
| Tall-VS-Follicular |
1.419880E-02 |
| Tall-VS-Other |
7.334600E-01 |
| Tall-VS-Normal |
3.41171535467311E-13 |
| Follicular-VS-Other |
3.983600E-01 |
| Follicular-VS-Normal |
7.79060149724842E-11 |
| Other-VS-Normal |
3.363200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
8.88178419700125E-16 |
| N0-vs-N1 |
1.662850E-03 |
|
|
